pentoxifylline has been researched along with Lupus Erythematosus, Systemic in 5 studies
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pentoxifylline (PTX) has a well-known therapeutic effect in vascular diseases, which is based on the rearrangement of blood cell cytoskeleton and thus increased microcirculatory flow." | 5.28 | Effect of pentoxifylline on decreased in vitro mononuclear leucocyte chemotaxis in vascular and polysystemic autoimmune diseases. ( Bedö, Z; Sonkoly, I; Szabó, G; Szegedi, G; Szekanecz, Z, 1991) |
| "Systemic lupus erythematosus is a polymorphic and multigenic inflammatory autoimmune disease." | 1.38 | Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. ( Bourguignon, JJ; Gazi, L; Keravis, T; Lugnier, C; Monneaux, F; Muller, S; Yougbaré, I, 2012) |
| "Pentoxifylline (PTX) has a well-known therapeutic effect in vascular diseases, which is based on the rearrangement of blood cell cytoskeleton and thus increased microcirculatory flow." | 1.28 | Effect of pentoxifylline on decreased in vitro mononuclear leucocyte chemotaxis in vascular and polysystemic autoimmune diseases. ( Bedö, Z; Sonkoly, I; Szabó, G; Szegedi, G; Szekanecz, Z, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keravis, T | 1 |
| Monneaux, F | 1 |
| Yougbaré, I | 1 |
| Gazi, L | 1 |
| Bourguignon, JJ | 1 |
| Muller, S | 1 |
| Lugnier, C | 1 |
| Shibata, S | 1 |
| Yamada, A | 1 |
| Miyagawa, Y | 1 |
| Szekanecz, Z | 2 |
| Szabó, G | 2 |
| Sonkoly, I | 2 |
| Bedö, Z | 2 |
| Szegedi, G | 2 |
| Segal, R | 1 |
| Dayan, M | 1 |
| Zinger, H | 1 |
| Mozes, E | 1 |
5 other studies available for pentoxifylline and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.
Topics: Adenine; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Progression; Fem | 2012 |
[Effects of pentoxifylline (Trental) on peripheral circulatory disorders in collagen and related diseases].
Topics: Adult; Collagen Diseases; Female; Humans; Lupus Erythematosus, Systemic; Male; Pentoxifylline; Theob | 1980 |
[Favorable in vitro effect of pentoxifylline on damaged lymphocyte migration in arteriosclerosis obliterans and systemic lupus erythematosus].
Topics: Arteriosclerosis Obliterans; Autoimmune Diseases; Chemotaxis; Humans; In Vitro Techniques; Leukocyte | 1993 |
Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline.
Topics: Animals; Antibodies, Monoclonal; Humans; Immunotherapy; Lupus Erythematosus, Systemic; Mice; Pentoxi | 2001 |
Effect of pentoxifylline on decreased in vitro mononuclear leucocyte chemotaxis in vascular and polysystemic autoimmune diseases.
Topics: Adult; Arteriosclerosis Obliterans; Autoimmune Diseases; Chemotaxis, Leukocyte; Female; Humans; In V | 1991 |